Navigation Links
Vela Laboratories Receives the GMP Certificate for Its Analytical and Quality Control Laboratories

VIENNA, April 7 /PRNewswire/ -- Vela Laboratories announced today that it has received the GMP certificate for its analytical and quality control laboratories. "Good Manufacturing Practice" is a body of internationally accepted regulations set forth by EU and US drug agencies. GMP compliance ensures that pharmaceuticals , active ingredients and medical devices are pro­duced and quality-controlled according to state-of-the-art standards.

"GMP compliance is the gold standard in quality assurance in the life science industry. It is a major achievement for Vela Labs to have reached the GMP certification just 18 months since its formation," said Dr. Markus Fido, founder and CEO of Vela Laboratories. "Now that Vela Laboratories is GMP certified, its analytical services fully qualify to support clinical studies as well as regulatory submissions."

"GMP certification is an important milestone for our analytical services business. Now we will start to consistently expand our analytical methods portfolio that we are offering to the pharmaceutical and biotech industry," said Dr. Andreas Nechansky, founder of Vela Labo­ratories and Chief Operating Officer.

"Having achieved GMP compliance enables Vela to develop its therapeutic anti-cancer anti­bodies in the shortest time possible and with the highest quality," said Dr. Ralf Kircheis, founder of Vela Laboratories and Chief Scientific Officer.

About Vela Laboratories

Vela Laboratories (Vela pharmazeutische Entwicklung und Laboranalytik GmbH) provides a broad portfolio of analytical methods for the preclinical and clinical development including studies in support of regulatory submissions and product release for biopharmaceuticals.

Additionally, Vela Laboratories develops innovative immunotherapeutics for the treatment of cancer, including therapeutic antibodies and multi-epitope vaccines. Vela Laboratories' lead product, a humanized monoclonal antibody against a common tumor antigen, is in clinical development. In addition, Vela Laboratories also has development programs underway that aim at improving the efficacy and tolerability of therapeutic antibodies through targeted changes to the sugar structure of the antibody molecules.

The Company, headquartered in Vienna, Austria, was founded in November 2006. Vela Laboratories is funded by private investors, by grants from Austrian government agencies (AWS and ZIT/LISA) and through revenues generated by its analytical services business.


Jakob Koschutnig

Head Marketing & Sales

Vela Laboratories

Brunner Str. 69 / 3

1230 Vienna, Austria

Mobile: +43(0)699-1314-3-123

Fax: +43(0)1-890-597-9-10



SOURCE Vela Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
2. Stonegate Report About Unigene Laboratories Inc.
3. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
4. White Paper Details Environmental Health & Safety Compliance Strategies for Laboratories
5. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
6. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
7. Clontech Laboratories, Inc. Releases the ProteoTuner(TM) Systems
8. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
9. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
10. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
11. Free White Paper Helps Biotech Laboratories Maintain a High Level of Infection Control
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
Breaking Biology Technology:
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
Breaking Biology News(10 mins):